SYK
Stryker Corporation
SYK
Stryker Corporation
Stryker (SYK) rebounded in Q2 with 9% organic growth, restoring confidence after a weak Q1. Both MedSurg & Neurotech and Orthopaedics segments sharply accelerated, indicating Q1 weakness was temporary
Stryker NYSE: SYK reported 9% organic sales growth in the second quarter of 2026 and adjusted earnings per share growth of 17.9%, as the medical technology company continued recovering from a cybersec